OBALON THERAPEUTICS, INC. (NASDAQ:OBLN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 9, 2016, the Compensation Committee of the Board of Directors of Obalon Therapeutics, Inc. (the “Company”), awarded to Andrew Rasdal, the Company’s President and Chief Executive Officer, (i) a one-time discretionary cash bonus of $250,000, (ii) an increase in his annual base salary from $400,000 per year to $650,000 per year, effective November 1, 2016, and (iii) an increase in his target bonus for 2017 from 30% of his annual base salary to 50% of his annual base salary.

About OBALON THERAPEUTICS, INC. (NASDAQ:OBLN)